Video

Dr Peter P. Yu Talks About the Importance of Patient-Centered Oncology Care

The American Journal of Managed Care's Patient-Centered Oncology Care meeting is an important event for anyone interested in "crossing the chasm" that appears between providers and the rest of the healthcare world, explained Peter P. Yu, MD, president of the American Society of Clinical Oncology.

The American Journal of Managed Care's Patient-Centered Oncology Care meeting is an important event for anyone interested in "crossing the chasm" that appears between providers and the rest of the healthcare world, including payers and hospital administrators, explained Peter P. Yu, MD, president of the American Society of Clinical Oncology, and the keynote speaker from Patient-Centered Oncology Care 2014.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
Dr Ibrahim Aldoss
Dr Pankit Vachhani
Mansi Shah, MD
Dr John Mascarenhas
CK Wang, MD, COTA
Dr Pankit Vachhani
Screenshot of Ivo Abraham, PhD, RN, during a video interview
Merrill H. Stewart, MD
Dr John Mascarenhas
Carla Nester, MD, MSA, FASN, Stead Family Children's Hospital
Related Content
Analyzed by birth cohort, the authors found each successive birth cohort had a 7.7% decline in SCLC rates. | Image credit: shidlovski
June 29th 2025

Decline in SCLC Incidence Expected to Accelerate Through 2050

Jared Kaltwasser
The incidence of small cell lung cancer (SCLC) is projected to drop by 5.9% each year through 2050.
Managed Care Cast
June 24th 2025

Addressing the Physical, Psychological Complexity of IBD Through Coordinated Care

Giuliana Grossi Skylar Jeremias Eva Szigethy, MD, PhD Benjamin Cohen, MD
Explore how the Specialty Medical Home model transforms care for patients with inflammatory bowel disease (IBD) by integrating mental health support and addressing stigma.
Doctor holding up image of fatty liver | Image credit: SoftSheep – stock.adobe.com
June 28th 2025

Weight Loss Drug HU6 Shows Promise in MASH With Muscle-Sparing Benefits

Hayden E. Klein
In the M-ACCEL trial, HU6-induced weight loss was exclusively attributed to fat loss, with no statistically significant loss in lean muscle.
Logo for Managed Care Cast
June 19th 2025

Stuck in Prior Auth Purgatory: The Hidden Costs of Health Care Delays

Maggie L. Shaw Colin Banas, MD, MHA
Delays, denials, and endless paperwork—prior authorization isn’t just a headache for providers; it’s a barrier for patients who need timely care, explains Colin Banas, MD, MHA, chief medical officer with DrFirst.
While elevated NLR previously served as a marker of aggressive disease and poor prognosis in SCLC, its prognostic relevance appears to diminish in the context of immunotherapy-based treatment regimens. | Image credit: Crystal light - stock.adobe.com
June 27th 2025

Challenging the Prognostic Role of NLR in SCLC in the Era of Immunotherapy

Kimberly Rath, PharmD
Elevated NLR may no longer predict poor survival outcomes in patients with small cell lung cancer (SCLC) receiving immunotherapy, according to new research.
A model suggested that a combination of 4 genes offered the best indicator of idiopathic pulmonary fibrosis. | Image Credit: CrazyJuke - stock.adobe.com
June 27th 2025

Differentially Expressed Genes May Serve as IPF Biomarkers

Jared Kaltwasser
The genes are all associated with cellular senescence, which is believed to play an important role in the development of idiopathic pulmonary fibrosis (IPF).

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo